Founders

Yehuda Zisapel

Founder and President

Yehuda ZisapelYehuda Zisapel holds an M.Sc. degree in Electronic Engineering from the Haifa Technion (Israel), an MBA from Tel-Aviv University
(Israel), and Doctor Honoris Causa from the Technion (Israel). He is the founder and director of the RAD Group, a holding that comprises 22 high-tech companies in computer communication technologies, six of which are publicly held and traded on the NASDAQ, and the chairman of Rad-Ramot Biomedical incubator. He has served as President of Neurim Pharmaceuticals since it commenced active operations in 1992.

Nava Zisapel

Founder and Chief Scientific Officer

Nava ZisapelNava Zisapel holds a B.Sc. in Chemistry, an M. Sc. in Biochemistry, and a Ph.D. in Biochemistry from Tel-Aviv University (Israel). She
is a full professor at Tel-Aviv University with a specialization in Neuro-biochemistry and the incumbent of the Michael Gluck Chair in Neuropharmacology and ALS Research. Nava Zisapel has authored with her students and collaborator scientists over 160 original research publications in peer-reviewed journals.

  • Text size: A A A
  • Circadin
  • Recent news

    • Positive Phase III Results for Neurim Pharmaceuticals’ Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder (ASD) Presented at the World Sleep Congress in Prague
    • Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by Flynn Pharma in UK and Ireland
    • Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th
  • Partners

    Partners